Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Multiparametric bone response assessment with Cabometyx in mCRPC
2021-000520-35Phase 2Completed
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Jun 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of cabozantinib in prostate cancer (PCa), sponsored by ASST Spedali Civili di Brescia. Primary endpoint: Primary endpoint: bone response by WB-DW-MRI. Started Jun 2021; status: completed.
02
Drugs
cabozantinib
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on 2021-000520-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-000520-35.